scholarly journals How does high meld score increases total expenditure on health system? A micro-costing prospective cohort study

2017 ◽  
Vol 20 (9) ◽  
pp. A882-A883
Author(s):  
JA Turri ◽  
LA Ferreira ◽  
TC Decimoni ◽  
AG Campolina
Keyword(s):  
Cohort Study ◽  
Health System ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Meld Score ◽  
Total Expenditure ◽  
System A

scholarly journals Cost of Living with Parkinson’s Disease over 12 Months in Australia: A Prospective Cohort Study

2017 ◽  
Vol 2017 ◽  
pp. 1-13 ◽  
Author(s):  
Shalika Bohingamu Mudiyanselage ◽  
Jennifer J. Watts ◽  
Julie Abimanyi-Ochom ◽  
Lisa Lane ◽  
Anna T. Murphy ◽  
...  
Keyword(s):  
Cohort Study ◽  
Health System ◽  
Prospective Cohort Study ◽  
Resource Use ◽  
Prospective Cohort ◽  
Annual Cost ◽  
Severe Disease ◽  
Medicare Data ◽  
The Mean

Background. Parkinson disease (PD) is a costly chronic condition in terms of managing both motor and nonmotor symptoms. The burden of disease is high for individuals, caregivers, and the health system. The aim of this study is to estimate the annual cost of PD from the household, health system, and societal perspectives. Methods. A prospective cohort study of newly referred people with PD to a specialist PD clinic in Melbourne, Australia. Participants completed baseline and monthly health resource use questionnaires and Medicare data were collected over 12 months. Results. 87 patients completed the 12-month follow-up assessments. The mean annual cost per person to the health care system was $32,556 AUD. The burden to society was an additional $45,000 per annum per person with PD. The largest component of health system costs were for hospitalisation (69% of total costs). The costs for people with moderate to severe disease were almost 4 times those with mild PD ($63,569 versus $17,537 p<0.001). Conclusion. PD is associated with significant costs to individuals and to society. Costs escalated with disease severity suggesting that the burden to society is likely to grow with the increasing disease prevalence that is associated with population ageing.

scholarly journals Retention in the Austrian opioid agonist treatment system: a national prospective cohort study

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Martin Busch ◽  
Charlotte Klein ◽  
Alfred Uhl ◽  
Hans Haltmayer ◽  
Maurice Cabanis ◽  
...  
Keyword(s):  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Retention In Care ◽  
Treatment Retention ◽  
Retention Rates ◽  
Opioid Agonist ◽  
System A ◽  
Using Data

Abstract Background Retention in care is a prerequisite for successful recovery, especially for a chronic condition like opioid dependence. Though retention varies greatly depending on the different substitution medication and treatment model, treatment retention is used as an indicator of treatment quality and effectiveness of care on a system and individual level. To monitor the overall quality of the Austrian opioid agonist treatment (OAT) system and to monitor patient satisfaction within the system, a new online-based registry called “eSuchmittel” was introduced in Austria at the beginning of 2011. The objective of this study is to analyze retention rates within the Austrian treatment system and to identify patient characteristics associated with retention, using data collected by the substitution registry. Methods The complete Austrian sample of 4778 registered patients starting treatment between 1.1.2011 to 31.12.2012 were included in the prospective cohort study using data from the Austrian substitution registry. For the statistical analysis, multivariate Cox Regression and Kaplan–Meier survival analysis were used to evaluate retention in treatment. Results The retention rate of the total cohort after two years was around 61%. Retention rates were significantly lower for men (exp(B) = .806, 95% CI 0.714–0.908) and significantly higher for patients aged 30 and older (exp(B) = 1.155, 95% CI 1.044–1.279), among patients located in Vienna (exp(B) = 1.439, 95% CI 1.273–1.626) and among patients prescribed oral slow-release morphine (SROM) (exp(B) = 2.141, 95% CI 1.885–2.430). Conclusions Average retention in the Austrian system is high in comparison to international retention rates. Nationally, SROM demonstrates higher treatment retention when compared to other available substitution medications. Sociodemographic and regional indicators also contribute to higher retention in care. A systematic monitoring of retention rates within a national registry is an important tool helping to evaluate the quality of care. In this study, the Austrian OAT system proves very high retention in care, an important success criterion.

Sign in / Sign up

Export Citation Format

Share Document